Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

March 23, 2018

European Respiratory Review 2018 March [Print 2018 March 31] Link] Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C Abstract Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have…

Read More

The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database

October 27, 2017

International Journal of Surgery 2017 October [Epub ahead of print] [Link] Wang S, Ma K, Wang Q, Sun F, Shi Y, Zhan C, Jiang W Abstract BACKGROUND: Several staging systems for MPM have been introduced. However, none of them provide perfect survival stratification among heterogeneous patients. The aim of this population-based cohort study was to…

Read More

Advances in systemic therapy for malignant mesothelioma: future perspectives

October 13, 2017

Future Oncology 2017 October [Epub ahead of print] [Link] Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D Abstract Malignant mesothelioma is a rare and aggressive form of cancer affecting the mesothelium. This mainly occupational disease is becoming more common in those countries where…

Read More

The value of delayed phase enhanced imaging in malignant pleural mesothelioma

September 29, 2017

Journal of Thoracic Disease 2017 August [Link] Patel AM, et.al. Abstract BACKGROUND: Cross-sectional imaging of malignant pleural mesothelioma (MPM) can underestimate the presence of local tumor invasion. Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed. Here we estimate the optimal timing of MPM enhancement on magnetic resonance…

Read More

Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining

September 23, 2017

Cancer. 2017 September 18 [Epub ahead of print] [Link] Mansour MSI, Seidal T, Mager U, Baigi A, Dobra K, Dejmek A Abstract BACKGROUND: Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD-L1) is a dominant mediator of immunosuppression, binding to programmed cell death…

Read More

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

July 13, 2017

Archives of pathology and laboratory medicine 2017 July [Epub ahead of print] [Link] Husain AN et.al. Abstract CONTEXT: – Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: – To provide updated, practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: – Pathologists involved in the International Mesothelioma Interest…

Read More

Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.

June 21, 2017

Tumor Biology 2017 June [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28618948″>Link Wang XY, Wang Z, Huang JB, Ren XD, Ye D1,, Zhu WW, Qin LXM Abstract BAP1 is an emerging tumor suppressor whose inactivating mutations have been found to play critical roles in tumor development. This study was conducted to elucidate the potential value of BAP1 mutation in guiding prognostic…

Read More

A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

April 18, 2017

Cancer Genomics & Protemics 2017 March [Link] Creaney J, Dick IM, Leon JS, Robinson BW Abstract Abstract Backgound/Aim: Malignant mesothelioma (MM) is an aggressive and fatal pleural cancer. The cell secretome offers information allowing insight into the pathogenesis of MM while offering the possibility to identify potential therapeutic targets and biomarkers. In the present study…

Read More